Dare Bioscience, Inc. (DARE) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
DARE Bioscience (DARE) Q1 2026: June Product Launch Unlocks First-Ever Direct Revenue Stream
May 15, 2026
-
DARE (DARE) Q4 2025: $13.9M Grant Offset Powers Pipeline, Commercial Launches Set for 2026
March 27, 2026
-
DARE (DARE) Q3 2025: R&D Expenses Drop 56% as Dual Path Strategy Targets Near-Term Revenue
November 14, 2025
-
DARE Bioscience (DARE) Q2 2025: R&D Spend Falls 71% as Dual Path Strategy Accelerates Commercial Launches
August 15, 2025